Eli Lilly and Company has announced plans to build four new pharmaceutical manufacturing sites in the United States. The medicine company believes that this initiative will bolster its domestic medicine production across therapeutic areas. With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.

According to the company, three of the newly announced manufacturing plants will focus on producing active pharmaceutical ingredients (API), which will allow for the reshoring of critical capabilities of small molecule chemical synthesis and further strengthen Lilly's supply chain. The final facility will extend Lilly’s global parenteral manufacturing network for future injectable therapies. The project is anticipated to create more than 3,000 new jobs.

What people are saying

In a recent quote, David A. Ricks, Lilly chair and CEO, said, "Lilly's optimism about the potential of our pipeline across therapeutic areas – cardiometabolic health, oncology, immunology and neuroscience – drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the U.S.A. This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future."

Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added, "To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines. We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care. This is a significant step for our company, our communities and the patients we serve."

Learn more about pharmaceutical manufacturing

Will 2025 be a good year for CDMOs?
This year’s outlook for the contract development and manufacturing organization market is cautiously optimistic. 

Process performance qualification pitfalls, and how to avoid them
Adhering to a tried-and-true set of best practices during the PPQ stage can prevent a drug approval from stalling out on the final lap.

Trump’s impact on biopharma industry may be a net positive in his new term
Donald Trump’s presidency is creating a sense of optimism in the sector, as he looks to implement an America First trade agenda including tariffs on China, Canada and Mexico.

Investing in American manufacturing in 2025

This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.